

IMMUNE DESIGN CORP.
Form SC 13D/A
February 28, 2019

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13D

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)**

(Amendment No. 1)*

IMMUNE DESIGN CORP.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

45252L103

(CUSIP Number)

Versant Venture Capital III, L.P.

Robin L. Praeger

One Sansome Street, Suite 3630

San Francisco, CA 94104

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

415-801-8100

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

CUSIP No. 45252L103

13D

1. Name of Reporting Persons
Versant Venture Capital III, L.P.
 2. Check the Appropriate Box if a Member of a Group (See Instructions)
 - (a)
 - (b) (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
Delaware, United States
- | | | | |
|---|-----|--------------------------|--------------------------------------|
| | 7. | Sole Voting Power | 2,195,251 shares of common stock (2) |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 8. | Shared Voting Power | 0 |
| | 9. | Sole Dispositive Power | 2,195,251 shares of common stock (2) |
| | 10. | Shared Dispositive Power | 0 |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,195,251 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
PN

(1) This Schedule 13D is filed by Versant Ventures III, LLC (VVIII-LLC), Versant Venture Capital III, L.P. (VVC-III), Versant Side Fund III, L.P. (VSF-III), Brian G. Atwood (Atwood), Bradley J. Bolzon (Bolzon), Samuel D. Colella (Colella), Ross A. Jaffe (Jaffe), William J. Link (Link), Barbara N. Lubash (Lubash), Donald B. Milder (Milder), Rebecca B. Robertson (Robertson), Robin L. Praeger (Praeger) and Charles Warden (Warden and, with VVIII-LLC, VVC-III, VSF-III, Atwood, Bolzon, Colella, Jaffe, Link, Lubash, Milder, Robertson and Praeger, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) These shares are held by VVC-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

CUSIP No. 45252L103

13D

- | | |
|-----|--|
| 1. | Name of Reporting Persons
Versant Side Fund III, L.P. |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) |
| | (a) <input type="radio"/> |
| | (b) <input checked="" type="radio"/> (1) |
| 3. | SEC Use Only |
| 4. | Source of Funds (See Instructions)
WC |
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) <input type="radio"/> |
| 6. | Citizenship or Place of Organization
Delaware, United States |
| | 7. Sole Voting Power
12,959 shares of common stock (2) |
| | 8. Shared Voting Power
0 |
| | 9. Sole Dispositive Power
12,959 shares of common stock (2) |
| | 10. Shared Dispositive Power
0 |
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
12,959 shares of common stock (2) |
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/> |
| 13. | Percent of Class Represented by Amount in Row 11
0.1% (3) |
| 14. | Type of Reporting Person (See Instructions)
PN |

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) These shares are held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

CUSIP No. 45252L103

13D

- | | |
|---|--|
| 1. | Name of Reporting Persons
Versant Ventures III, LLC |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) |
| | (a) <input type="radio"/> |
| | (b) <input checked="" type="radio"/> (1) |
| 3. | SEC Use Only |
| 4. | Source of Funds (See Instructions)
WC |
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) <input type="radio"/> |
| 6. | Citizenship or Place of Organization
Delaware |
| | 7. Sole Voting Power
0 |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 8. Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. Sole Dispositive Power
0 |
| | 10. Shared Dispositive Power
2,208,210 shares of common stock (2) |
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2) |
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/> |
| 13. | Percent of Class Represented by Amount in Row 11
4.6% (3) |
| 14. | Type of Reporting Person (See Instructions)
OO |

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018. 24, 2014.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Brian G. Atwood
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) (1)
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
7,339 shares of common stock (2) |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (3) |
| | 9. | Sole Dispositive Power
7,339 shares of common stock (2) |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (3) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,215,549 shares of common stock (2)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11
4.6% (4)
14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Represents 7,339 shares of common stock held by Atwood.

(3) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(4) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Ross A. Jaffe
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
United States
- | | | | |
|---|-----|--------------------------|--------------------------------------|
| | 7. | Sole Voting Power | 0 |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 8. | Shared Voting Power | 2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power | 0 |
| | 10. | Shared Dispositive Power | 2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Samuel D. Colella
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) (1)
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
0 |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power
0 |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11
4.6% (3)
14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Donald B. Milder
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) (1)
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
0 |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power
0 |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11
4.6% (3)
14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Rebecca B. Robertson
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
0 |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power
0 |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Bradley J. Bolzon
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
Canada
- | | | |
|-----|--------------------------|--------------------------------------|
| 7. | Sole Voting Power | 0 |
| 8. | Shared Voting Power | 2,208,210 shares of common stock (2) |
| 9. | Sole Dispositive Power | 0 |
| 10. | Shared Dispositive Power | 2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
William J. Link
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) (1)
3. SEC Use Only
4. Source of Funds (See Instructions)
WC
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
0 |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power
0 |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11
4.6% (3)
14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Charles M. Warden
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
United States
- | | | |
|---|-----|--|
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 7. | Sole Voting Power
0 |
| | 8. | Shared Voting Power
2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power
0 |
| | 10. | Shared Dispositive Power
2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Barbara N. Lubash
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
United States
- | | | | |
|---|-----|--------------------------|--------------------------------------|
| | 7. | Sole Voting Power | 0 |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 8. | Shared Voting Power | 2,208,210 shares of common stock (2) |
| | 9. | Sole Dispositive Power | 0 |
| | 10. | Shared Dispositive Power | 2,208,210 shares of common stock (2) |
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

1. Name of Reporting Persons
Robin L. Praeger
 2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)	<input type="radio"/>
(b)	<input checked="" type="radio"/> (1)
 3. SEC Use Only
 4. Source of Funds (See Instructions)
WC
 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)
 6. Citizenship or Place of Organization
United States
- | | | |
|-----|--------------------------|--------------------------------------|
| 7. | Sole Voting Power | 0 |
| 8. | Shared Voting Power | 2,208,210 shares of common stock (2) |
| 9. | Sole Dispositive Power | 0 |
| 10. | Shared Dispositive Power | 2,208,210 shares of common stock (2) |
- Number of Shares Beneficially Owned by Each Reporting Person With
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,208,210 shares of common stock (2)
 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
 13. Percent of Class Represented by Amount in Row 11
4.6% (3)
 14. Type of Reporting Person (See Instructions)
IN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes (i) 2,195,251 shares held by VVC-III; and (ii) 12,959 shares held by VSF-III. Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(3) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

Edgar Filing: IMMUNE DESIGN CORP. - Form SC 13D/A

CUSIP No. 45252L103

13D

Explanatory Note: This 13D relates to shares of Common Stock, \$0.001 par value per share (Common Stock), of Immune Design Corp., a Delaware corporation (the Issuer or Immune Design).

Item 1. Security and Issuer

The class of equity security to which this statement on Schedule 13D relates is the common stock, par value \$0.001 per share (the Common Stock) of Immune Design Corp., a corporation organized under the laws of the state of Delaware (the Company). The address of the principal executive offices of the Company is 1616 Eastlake Avenue E., Suite 310, Seattle, Washington 98102. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 2. Identity and Background

(a) This Schedule 13D is filed by Versant Ventures III, LLC (VVIII-LLC), Versant Venture Capital III, L.P. (VVC-III), Versant Side Fund III, L.P. (VSF-III), Brian G. Atwood (Atwood), Bradley J. Bolzon (Bolzon), Samuel D. Colella (Colella), Ross A. Jaffe (Jaffe), William J. Link (Link), Barbara N. Lubash (Lubash), Donald B. Milder (Milder),

Rebecca B. Robertson (Robertson), Robin L. Praeger (Praeger) and Charles M. Warden (Warden and, with VVIII-LLC, VVC-III, VSF-III, Atwood, Bolzon, Colella, Jaffe, Link, Lubash, Milder, Robertson and Praeger, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(b) The principal business and principal business office of the Reporting Persons is Versant Ventures, One Sansome Street, Suite 3630, San Francisco, CA 94104.

(c) The principal business of the Reporting Persons is venture capital investments. Each of the individuals serves as a managing director of VVIII-LLC, which is the general partner of VVC-III and VSF-III.

(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Each of VVIII-LLC, VVC-III and VSF-III are incorporated in the state of Delaware and each of the individuals, except for Bolzon is a citizen of the United States. Bolzon is a citizen of Canada.

Item 3. Source and Amount of Funds or Other Consideration

Item 4. Purpose of Transaction

The Reporting Persons ceased to be beneficial owners of more than 5% of the issued and outstanding Common Stock of the Issuer. The reporting obligations of the Reporting Persons with respect to the Common Stock pursuant to Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder are therefore terminated.

Item 5.**Interest in Securities of the Issuer**

The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of December 31, 2018:

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power(1)	Sole Dispositive Power	Shared Dispositive Power (1)	Beneficial Ownership	Percentage of Class (2)
VVC-III	2,195,251	2,195,251	0	2,195,251	0	2,195,251	4.6%
VSF-III	12,959	12,959	0	12,959	0	12,959	0.1%
VVIII-LLC	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Atwood	7,339	7,339	2,208,210	7,339	2,208,210	2,215,549	4.6%
Bolzon	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Colella	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Jaffe	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Link	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Lubash	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Milder	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Robertson	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Praeger	0	0	2,208,210	0	2,208,210	2,208,210	4.6%
Warden	0	0	2,208,210	0	2,208,210	2,208,210	4.6%

(1) Atwood, Jaffe, Colella, Milder, Robertson, Bolzon, Link, Warden, Praeger and Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by VVC-III and VSF-III.

(2) The percentages used herein are calculated based upon 48,164,828 shares issued and outstanding as of November 5, 2018, as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2018.

(c) Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer's Common Stock during the last 60 days.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 7. Materials to be Filed as Exhibits.

Exhibit 1: Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 28, 2019

Versant Venture Capital III, L.P.

By: Versant Ventures III, LLC
Its: General Partner

By: /s/ Robin L. Praeger

Versant Side Fund III, L.P.

By: Versant Ventures III, LLC
Its: General Partner

By: /s/ Robin L. Praeger

Versant Ventures III, LLC

By: /s/ Robin L. Praeger

*
Brian G. Atwood

*
Bradley J. Bolzon

*
Samuel D. Colella

*
Ross A. Jaffe

*
William J. Link

*
Barbara N. Lubash

*
Donald B. Milder

*
Rebecca B. Robertson

*
Charles M. Warden

*
Robin L. Praeger

Exhibit 1

Joint Filing Agreement

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Immune Design Corp. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

February 28, 2019

Versant Venture Capital III, L.P.

By: Versant Ventures III, LLC
Its: General Partner

By: /s/ Robin L. Praeger

Versant Side Fund III, L.P.

By: Versant Ventures III, LLC
Its: General Partner

By: /s/ Robin L. Praeger

Versant Ventures III, LLC

By: /s/ Robin L. Praeger

*
Brian G. Atwood

*
Bradley J. Bolzon

*
Samuel D. Colella

*
Ross A. Jaffe

*
William J. Link

*
Barbara N. Lubash

*
Donald B. Milder

*

Rebecca B. Robertson

*

Charles M. Warden

*

Robin L. Praeger